An interventional study of Repetitive transcranial magnetic stimulation and Sham repetitive transcranial magnetic stimulation in Depression During Pregnancy, Postpartum Depression (PPD) and Peripartum Depression, sponsored by Psychiatric University Hospital, Zurich. Recruiting at 2 sites in Switzerland. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Psychiatric University Hospital, Zurich · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to learn whether repetitive transcranial magnetic stimulation (rTMS) can reduce depressive symptoms in women who are pregnant or up to 12 months after childbirth and have peripartum depression. rTMS is a non-invasive treatment in which a device placed on the scalp delivers gentle magnetic pulses to a brain area involved in mood regulation. It does not involve medication or anaesthesia.
The main questions this study aims to answer are:
Researchers will compare active rTMS with sham rTMS, a treatment designed to feel and sound similar but not to provide effective brain stimulation. Neither participants nor the clinicians assessing depressive symptoms will know which treatment was assigned during the main study phase.
Up to 60 women aged 18 years or older who are pregnant or up to 12 months after childbirth and have clinically relevant depressive symptoms may take part. Participants will:
Each treatment visit lasts about 30 minutes, including preparation, treatment, and a short safety check. Infants may be brought to treatment visits when this can be done safely.
rTMS is generally well tolerated. Possible temporary side effects include headache, scalp discomfort, facial muscle twitching during stimulation, dizziness, or tiredness. A seizure is a very rare but serious possible risk; therefore, people with epilepsy, certain implants, or other relevant risk factors cannot take part.
Participation is voluntary. Participants can pause or stop participation at any time without affecting their usual care. Personal data will be coded and handled confidentially. Women assigned to sham treatment will be offered active rTMS after the blinded study phase, if they wish. The results may help clarify whether rTMS is an effective non-medication treatment option for peripartum depression.
Peripartum depression is depression that occurs during pregnancy or within the first year after childbirth. It can affect mood, energy, sleep, daily functioning, relationships, and the ability to enjoy pregnancy or early parenthood. Treatment options during this period may be limited because some people prefer to avoid medication, have concerns about medication during pregnancy or breastfeeding, or do not improve sufficiently with their current treatment.
This clinical trial is investigating repetitive transcranial magnetic stimulation (rTMS) as a possible non-medication treatment for peripartum depression. rTMS is a non-invasive treatment in which a coil placed on the scalp delivers short magnetic pulses to a brain area involved in mood regulation. It does not involve surgery, medication, or anaesthesia. rTMS is already used to treat depression in adults; however, more research is needed to understand its effects specifically during pregnancy and after childbirth.
The study will include up to 60 women aged 18 years or older who are pregnant or up to 12 months after giving birth and have clinically relevant depressive symptoms. Before joining the study, interested individuals will receive written study information and have an opportunity to ask questions. Participation begins only after written informed consent has been provided.
At the baseline visit, the study team will review medical, psychiatric, and obstetric history and confirm eligibility. Participants will complete questionnaires about depressive symptoms, wellbeing, quality of life, social support, treatment expectations, and related topics. EEG and ECG recordings will be performed before treatment. Small hair and sputum samples will also be collected to explore stress-related and other hormone levels. These samples will not be used for genetic testing.
Eligible participants will be assigned by chance, in a 1:1 ratio, to receive either active rTMS or sham rTMS. Sham rTMS uses a special coil designed to produce similar sounds and scalp sensations without delivering effective stimulation to the brain. During the main study phase, participants and the clinicians assessing depressive symptoms will not know which treatment has been assigned. This design allows researchers to compare the effects of active rTMS and sham treatment fairly.
Participants will usually receive two sessions per day on five days per week. To accommodate childcare, breastfeeding, fatigue, medical appointments, and other individual needs, the schedule can be adjusted. Participants may receive between one and four sessions per day, with at least 30 minutes between sessions, and must attend at least three sessions per week. Treatment may therefore be completed over approximately 1.5 to 10 weeks. Each visit lasts around 30 minutes, including preparation, treatment, and a safety check. Infants may be brought to treatment appointments when this can be done safely.
The main aim is to determine whether active rTMS reduces depressive symptoms more than sham rTMS from the start to the end of treatment. The study will also assess changes in self-reported mood, quality of life, social support, and other aspects of wellbeing. EEG and ECG recordings will be repeated after treatment. Participants will be contacted by telephone one month after treatment to assess whether any change in depressive symptoms continues. One year after treatment, participants will be invited to complete a short questionnaire about their child's development.
rTMS is generally well tolerated. Possible temporary side effects include headache, scalp discomfort, facial muscle twitching during stimulation, dizziness, or tiredness. A seizure is a very rare but serious potential risk. To reduce risks, individuals with epilepsy, certain metal or electronic implants, or medical or obstetric conditions that could make participation unsafe will not be included. Safety and any side effects will be assessed and documented before or during every treatment session.
Participation is voluntary. Participants may pause or withdraw from the study at any time without affecting their present or future medical care. Personal information will be coded and handled confidentially. Participants assigned to sham rTMS will be offered the option to receive active rTMS after they have completed the blinded study phase. The findings may help determine whether rTMS could become a useful non-medication treatment option for people with peripartum depression.
569 studies on the registry are indexed under Depression, Postpartum; 134 are open to participants now.
This study's planned enrollment of 60 is below the median of 104 across 454 interventional studies indexed under Depression, Postpartum.
Browse Depression, Postpartum studies →Psychiatric University Hospital, Zurich is the lead sponsor of 22 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 30 sessions of active high-frequency rTMS targeting the left dorsolateral prefrontal cortex.
Device: Repetitive transcranial magnetic stimulation
Participants receive 30 sessions of sham rTMS using a validated sham coil that reproduces the sound and scalp sensations of active rTMS without effective brain stimulation.
Device: Sham repetitive transcranial magnetic stimulation
Active repetitive transcranial magnetic stimulation (rTMS) is delivered to the left dorsolateral prefrontal cortex using a CE-marked MagVenture MagPro system with a figure-of-eight coil. Stimulation is delivered at 10 Hz and at 80-120% of the individual resting motor threshold, with 1,200 pulses per session. Participants are scheduled to receive 30 sessions.
Also known as: High-frequency rTMS, transcranial magnetic stimulation
Sham repetitive transcranial magnetic stimulation (sham rTMS) is delivered using a validated sham coil. The sham procedure matches active rTMS in coil positioning, treatment schedule, device displays, sounds, and scalp sensations, but does not provide effective stimulation to the brain. Participants are scheduled to receive 30 sham sessions using the same flexible scheduling as the active-rTMS group.
Change in depressive symptoms measured by the Montgomery-Åsberg Depression Rating Scale (MADRS)
Depressive symptom severity will be assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS) at baseline and at the end of the assigned treatment phase. The primary outcome is the change in MADRS score from baseline to the end of treatment, compared between the active-rTMS and sham-rTMS groups. The Montgomery-Åsberg Depression Rating Scale (MADRS) measures the severity of depressive symptoms. Possible scores range from 0 to 60, with higher scores indicating more severe depression
Time frame: at baseline and at the end of treatment (up to 10 weeks)
Change in Beck Depression Inventory-II (BDI-II) score
Depressive symptoms will be assessed using the Beck Depression Inventory-II (BDI-II) at baseline and at the end of the assigned treatment phase. The secondary outcome is the change in BDI-II score from baseline to the end of treatment, compared between the active-rTMS and sham-rTMS groups. The Beck Depression Inventory, Second Edition (BDI-II) measures the severity of depressive symptoms. Possible scores range from 0 to 63, with higher scores indicating more severe depression.
Time frame: at baseline and at the end of treatment (up to 10 weeks)
Change in Edinburgh Postnatal Depression Scale (EPDS) score
Peripartum depressive symptoms will be assessed weekly using the Edinburgh Postnatal Depression Scale (EPDS). Change in EPDS score from baseline to the end of treatment will be compared between treatment groups. The Edinburgh Postnatal Depression Scale (EPDS) measures the severity of depressive symptoms in the perinatal period. Possible scores range from 0 to 30, with higher scores indicating more severe depressive symptoms.
Time frame: at baseline, weekly during treatment, and end of treatment (up to 10 Weeks)
Change in Clinical Global Impression (CGI) score
Overall clinical status will be assessed using the Clinical Global Impression (CGI) scale at baseline and at the end of treatment. Change in CGI score will be compared between treatment groups. The Clinical Global Impression - Severity scale (CGI-S) measures the clinician's global rating of illness severity. Possible scores range from 1 to 7, with higher scores indicating greater illness severity.
Time frame: at baseline and at the end of treatment (up to 10 weeks)
Change in Mental Health Quality of Life (MHQoL) score
Mental health-related quality of life will be assessed using the Mental Health Quality of Life (MHQoL) questionnaire. Change in MHQoL score from baseline to the end of treatment will be compared between treatment groups. The Mental Health Quality of Life Questionnaire, 7-dimension index (MHQoL-7D), measures mental health-related quality of life across seven domains. Possible scores range from 0 to 21, with higher scores indicating better mental health-related quality of life.
Time frame: at baseline and at the end of treatment (up to 10 weeks)
Change in Multidimensional Scale of Perceived Social Support (MSPSS) score
Perceived social support will be assessed using the Multidimensional Scale of Perceived Social Support (MSPSS). Change in MSPSS score from baseline to the end of treatment will be compared between treatment groups. The Multidimensional Scale of Perceived Social Support (MSPSS) measures perceived social support from family, friends, and significant others. Possible scores range from 12 to 84, with higher scores indicating greater perceived social support.
Time frame: at baseline and at the end of treatment (up to 10 weeks)
Change in Suicidal Behaviors Questionnaire-Revised (SBQ-R) score
Suicidal thoughts and behaviours will be assessed using the Suicidal Behaviors Questionnaire-Revised (SBQ-R). Change in SBQ-R score from baseline to the end of treatment will be compared between treatment groups. The Suicidal Behaviors Questionnaire-Revised (SBQ-R) measures risk of suicidal behavior. Possible scores range from 3 to 18, with higher scores indicating greater suicide risk.
Time frame: at baseline and at the end of treatment (up to 10 weeks)
Change in Food Frequency Items (FFI) score
Dietary habits will be assessed using Food Frequency Items (FFI). Change in FFI score from baseline to the end of treatment will be compared between treatment groups. The Food Frequency Items (FFI) is a questionnaire to record participants' dietary intake patterns, results are reported descriptively by food category.
Time frame: at baseline and at the end of treatment (up to 10 weeks)
Change in General Self-Efficacy Scale (GSES) score
Self-efficacy will be assessed using the General Self-Efficacy Scale (GSES). Change in GSES score from baseline to the end of treatment will be compared between treatment groups. The General Self-Efficacy Scale (GSES) measures a person's belief in their own ability to cope with challenging situations. Possible scores range from 10 to 40, with higher scores indicating greater self-efficacy.
Time frame: at baseline and at the end of treatment (up to 10 weeks)
Change in Treatment Expectation Questionnaire (TEX-Q) score
Treatment expectations will be assessed using the Treatment Expectation Questionnaire (TEX-Q). TEX-Q scores will be assessed in relation to the assigned treatment and compared between treatment groups. The Treatment Expectation Questionnaire (TEX-Q) assesses patients' expectations regarding the treatment's anticipated benefits, adverse effects, and impact on daily functioning across several subscales, each rated on an 11-point scale (0-10). Because the subscales are interpreted separately and higher scores do not indicate a uniformly better or worse outcome across all of them, subscale scores are reported individually rather than as a single combined range.
Time frame: at baseline and at the end of treatment (up to 10 weeks)
Blinding credibility assessed by the Blinding Credibility Questionnaire (BCQ)
At the end of treatment, participants will indicate whether they believe they received active or sham rTMS and how confident they are in that assessment. The Blinding Credibility Questionnaire (BCQ) asks participants to indicate whether they believe they received active or sham rTMS and to rate their confidence in that belief. It does not produce a single summed score with a minimum, maximum, or direction; results are reported as the proportion of participants correctly/incorrectly guessing their treatment allocation, together with their confidence ratings.
Time frame: End of treatment (up to 10 weeks)
Change in MADRS score at 1-month follow-up
Depressive symptom severity will be assessed using the MADRS during a telephone follow-up. Change in MADRS score from baseline to one month after treatment will be compared between treatment groups. The Montgomery-Åsberg Depression Rating Scale (MADRS) measures the severity of depressive symptoms. Possible scores range from 0 to 60, with higher scores indicating more severe depression
Time frame: at baseline, at the end of treatment and 1 month after completion of the rTMS treatment
Change in electroencephalography (EEG) measures
EEG recordings will be obtained before and after treatment. Changes in predefined EEG measures will be compared between treatment groups. EEG recordings are analyzed for spectral power in five standard frequency bands (delta, theta, alpha, beta, and gamma, the latter further divided into two sub-bands), together with Alpha Peak Frequency, Frontal Alpha Asymmetry, and EEG-vigilance regulation. The baseline EEG recording additionally serves a safety-screening purpose, identifying epileptiform potentials to to exclude participants with evidence of clinical or subclinical epilepsy prior to initiating rTMS, per the study's exclusion criteria.
Time frame: at baseline and at the end of treatment (up to 10 weeks)
Change in electrocardiography (ECG) measures
ECG recordings will be obtained before and after treatment. Changes in predefined ECG measures will be compared between treatment groups. ECG recordings are analyzed via heart-rate variability derived from the R-R interval series, parameters include heart rate, heart-rate regulation slope, absolute HRV power, low-frequency and high-frequency spectral power, and the relative sympathetic activity index.
Time frame: at baseline and at the end of treatment (up to 10 weeks)
Hormone levels in hair and sputum samples
Hair and sputum samples will be collected to assess stress-related and other hormone levels. Samples will be analysed according to the study laboratory procedures.
Time frame: at baseline
Child development assessed by Parents' Evaluation of Developmental Status (PEDS)
Participants will complete the Parents' Evaluation of Developmental Status (PEDS) questionnaire to identify possible developmental concerns in their child. The Parents' Evaluation of Developmental Status (PEDS) Response Form elicits parents' concerns about their child's development, behavior, and mental health across several domains (e.g., language, motor skills, social-emotional functioning, self-help). It does not produce a single summed score with a minimum, maximum, or direction.
Time frame: 12 months after completion of the rTMS treatment
Incidence and severity of adverse events
Adverse events, including rTMS-related symptoms such as headache, scalp discomfort, dizziness, fatigue, or facial muscle twitching, will be assessed and documented at every treatment session. Serious adverse events will be recorded and evaluated according to study safety procedures.
Time frame: From randomization through end of treatment, assessed at each of the 30 rTMS sessions (up to 10 Weeks)
Plan to share: Undecided — At present, it is not yet clear which datasets will be suitable and permissible for sharing. The study team is interested in sharing de-identified data with qualified collaborators after completion of the primary analyses; however, final decisions will depend on ethical, legal, institutional, and data-protection requirements. If a data-sharing plan is implemented, the ClinicalTrials.gov record will be updated accordingly.
Started Oct 2026 (actual). Primary completion is estimated for Aug 2030, 46 months after the start.
Of 256 non-industry interventional studies with no phase under Depression, Postpartum, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 36. This study's planned 46 months is above that.
Counting every sponsor, half of 262 studies reached it within 23 months; a quarter within 11 and three quarters within 36.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 3, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Psychiatric University Hospital, Zurich